Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date
2750 results found
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
Newborn Children Adolescents Adults Pneumococcal disease Rotavirus Human papillomavirus (HPV) Meningococcal disease Mumps Measles Rubella Economic aspects
Rating:
Not applicable
2023 ∙ Dadari, I. Belt, R. V. Iyengar, A. Ray, A. Hossain, I. Ali, D. Danielsson, N. Sodha, S. V.
Achieving the IA2030 Coverage and Equity Goals through a Renewed Focus on Urban Immunization
Newborn Children Adolescents Coverage Ethical issues
Rating:
Not applicable
2023 ∙ Amisha, F. Saluja, P. Malik, P. Van Rhee, F.
Acquired hemophilia A (AHA) due to anti-SARS-CoV-2 vaccination: A systematic review
Adults Older adults COVID-19 Safety
Rating:
Critically low
2023 ∙ Nabizadeh, F. Noori, M. Rahmani, S. Hosseini, H.
Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review
Adults Older adults COVID-19 Safety
Rating:
Critically low
2023 ∙ Pichichero, Michael Malley, Richard Kaur, Ravinder Zagursky, Robert Anderson, Porter
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines
Children Adolescents Pneumococcal disease Efficacy/effectiveness Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Liatsou, E. Ntanasis-Stathopoulos, I. Lykos, S. Ntanasis-Stathopoulos, A. Gavriatopoulou, M. Psaltopoulou, T. Sergentanis, T. N. Terpos, E.
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Adults Older adults COVID-19 Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Putri, E. A. C. Munir, M. Setiawan, H. K. Herawati, L. Sari, G. M. Wungu, C. D. K. Susilo, H. Sutanto, H.
Adverse cardiac events following mRNA COVID-19 vaccination: A systematic review and meta-analysis
Adolescents Adults Older adults COVID-19 Safety
Rating:
Critically low
2023 ∙ Yasmin, F. Najeeb, H. Naeem, U. Moeed, A. Atif, A. R. Asghar, M. S. Nimri, N. Saleem, M. Bandyopadhyay, D. Krittanawong, C. Fadelallah Eljack, M. M. Tahir, M. J. Waqar, F.
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
All age groups COVID-19 Safety
Rating:
Critically low
2023 ∙ Zhang, H. Q. Cao, B. Z. Cao, Q. T. Hun, M. Cao, L. Zhao, M. Y.
An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination
Adults Older adults COVID-19 Safety
Rating:
Critically low
2023 ∙ Bachour, Y.
An update and overview of the literature on late inflammatory reactions (LIRs) in soft tissue fillers after SARS-CoV-2 infection and vaccination
All age groups COVID-19 Safety
Rating:
Critically low
Loading...